Skip to content
    Reviews

    Review: Orforglipron Tolerability Is Not Superior to Injectable Peptides

    Habib et alEndocrine

    Review: Orforglipron Tolerability Is Not Superior to Injectable Peptides
    Oral small-molecule glucagon-like peptide-1 receptor agonists (GLP-1RAs) offer practical advantages over peptide formulations by removing injection burdens, cold-chain dependence, and fasting requirements, but they present distinct pharmacological and tolerability profiles. A narrative review synthesizing Phase 3 trial data, receptor pharmacology, network meta-analyses, and regulatory prescribing information highlights orforglipron, the most clinically advanced small molecule in this class, while considering early-phase data for GSBR-1290 and CT-996 as hypothesis-generating.
    Pharmacologically, orforglipron binds a non-canonical orthosteric pocket and elicits Gs-protein-biased signalling. Its metabolic route relies on hepatic CYP3A4 metabolism with 87% faecal elimination; this profile eliminates the need for renal dose adjustment but introduces drug-interaction and hepatic-impairment liabilities not seen with peptide GLP-1RAs. Shared class risks remain present, including pancreatitis, gallbladder disease, acute kidney injury, and a boxed warning for thyroid C-cell tumour.
    Gastrointestinal adverse events persist as the primary class-effect liability. In the ATTAIN-1 trial, nausea occurred in 33.7% of participants receiving orforglipron 36 mg (an investigational capsule dose equivalent to the approved 17.2 mg tablet dose), with an adverse-event discontinuation rate of 10.3%. Furthermore, head-to-head data from ACHIEVE-3 revealed that orforglipron led to approximately twice the discontinuation rate observed with oral semaglutide, indicating that gastrointestinal tolerability is not superior to injectable or oral peptide alternatives. A six-step dose-escalation protocol requiring a minimum of 30 days per step serves as the primary modifiable variable to manage tolerability.
    In the ACHIEVE-4 trial, cardiovascular non-inferiority to insulin glargine was shown for orforglipron. However, the review concludes that placebo-controlled outcome trials remain necessary before cardiovascular or renal benefits can be assumed, and findings from orforglipron should not be generalized to other oral small-molecule agents.

    Key Takeaways

    • In clinical evaluations, orforglipron 36 mg resulted in a 33.7% rate of nausea and a 10.3% adverse-event discontinuation rate in ATTAIN-1, producing approximately twice the discontinuation rate of oral semaglutide in ACHIEVE-3.
    • Orforglipron undergoes hepatic CYP3A4 metabolism with 87% faecal elimination, avoiding renal dose adjustments but introducing drug-interaction and hepatic-impairment liabilities absent with peptide formulations.
    • While achieving cardiovascular non-inferiority to insulin glargine in ACHIEVE-4, orforglipron shares class-wide safety warnings for pancreatitis, gallbladder disease, acute kidney injury, and thyroid C-cell tumours.